Background
==========

Pulmonary hypertension (PH) regardless of etiology has been associated with increased morbidity and mortality. In patients with end-stage renal disease (ESRD) requiring chronic hemodialysis (HD) retrospective record reviews of largely non-US populations suggest that PH occurs in about 25%--45% of patients.[@b1-ijgm-3-279]--[@b3-ijgm-3-279] Various mechanisms have been postulated for its development, including disturbances in endothelial and vascular smooth muscle function,[@b4-ijgm-3-279],[@b5-ijgm-3-279] high output state[@b3-ijgm-3-279],[@b6-ijgm-3-279] related to grafts and fistulas, microbubble pulmonary emboli[@b7-ijgm-3-279] and pre-existing or acquired left-sided cardiac dysfunction. [@b3-ijgm-3-279],[@b8-ijgm-3-279] It is estimated that there are about 350,000 people receiving chronic HD in the US.[@b9-ijgm-3-279] The US dialysis patient demographic differs substantially from other reported populations with theoretically different prevalence and outcome of PH. Despite the potential burden of pulmonary hypertension in this large population, prospective data regarding the prevalence of PH, clinical determinants, and prognostic significance is limited. Thus, the purpose of this study was to prospectively determine the prevalence of PH by echocardiography in dialysis patients in a single dialysis center in the US and identify the clinical significance of PH on all-cause mortality and morbidity.

Methods
=======

We prospectively performed predialysis echocardiograms on all patients routinely attending a single dialysis center. Echocardiograms were performed predialysis as opposed to post dialysis as it was felt that the predialysis status of the patient more closely reflects the chronic volume status of the patient than the immediate post dialysis "dry weight" state. Baseline demographics were collected through review of the medical records. It was attempted to consent, enroll, and recover data on all the patients in this dialysis unit. All aspects of this study were approved by the Baylor institutional review board, Fresenius (the dialysis unit operator), and the medical director(s) of the dialysis unit.

Echocardiograms and estimation of pulmonary hypertension
--------------------------------------------------------

Complete echocardiograms (2-dimensional, M-Mode, and Doppler studies) were performed (using the Biosound system), digitally stored and analyzed. Standard 2D echocardiographic parameters of cardiac structure and function, Doppler assessment of pulmonary veins, mitral inflow, tricuspid inflow, left ventricular outflow tract, as well as tissue Doppler imaging at the mitral and tricuspid annulus were acquired with the patient in the left lateral position according to recommendations from the American Society of Echocardiography.[@b10-ijgm-3-279]--[@b13-ijgm-3-279] All echocardiograms were analyzed by a single reader, who was aware that all patients were dialysis-dependent patients but was blinded to additional clinical and outcomes data.

Previous studies calculated pulmonary artery systolic pressure (PAP) echocardiographically using the Bernoulli equation: PAP = 4 × (peak tricuspid regurgitant (TR) jet velocity)[@b2-ijgm-3-279] + 10 mmHg (estimated right atrial pressure (RAP)). As the RAP estimate is yet another estimate, to maximize the integrity of the data, PH was defined by the TR jet only. Thus, in the present study, PH was defined as a TR jet ≥2.5 m/s (this would be approximately equivalent to PAP ≥35 mmHg assuming a RAP of 10 mmHg); 'more severe PH' as TR jet ≥3.0 m/s. This methodology would underestimate PAP compared with prior studies but would more strictly define patients with PH. Patients with insufficient TR jet who had echo-Doppler characteristics similar to those with normal TR jet velocity and no indirect echo-Doppler evidence of PH (37 patients), were grouped with patients without PH (11 patients). Patients were divided into 3 groups based on peak TR jet velocity: group 1, no TR and TR \<2.5 m/s; group 2, TR 2.5--3.0 m/s; group 3, TR \>3.0 m/s.

Clinical outcomes
-----------------

Data on all-cause hospitalizations and death at 4, 8, and 12 months post echocardiogram was collected. For hospitalization data, complete follow up was available in 76 patients. For the survival analysis, all 90 patients were accounted for either through chart review or the United States Renal Data System database. The research nurse recording outcomes data was blinded to the results of the echo data.

Statistical analysis
--------------------

Differences across the 3 groups were examined using ANOVA for continuous variables and the Chi-square test for categorical variables. Variables that were not normally distributed were examined using non-parametric tests. The data are presented as mean and standard deviation unless otherwise specified.

For survival analysis, Kaplan Meier survival curves were generated, and a log rank test was used to assess for statistically significant differences between the groups.

Results
=======

Of 133 patients attending the dialysis clinic, 103 consented to participation between May 2006 and May 2007. 10 patients relocated prior to completion of the echocardiogram, and 3 patients were excluded due to technically inadequate echocardiograms. Thus, the cohort consisted of 90 consecutively consented and enrolled patients.

Clinical characteristics
------------------------

The baseline characteristics of the patients are shown in [Table 1](#t1-ijgm-3-279){ref-type="table"}. The majority of patients were male (66%), with an average age of 58 ± 15 years. 64% of the patients were African American, 18% were Hispanic, and 18% Caucasian. The most frequent cause of ESRD requiring HD was a combination of diabetes and hypertension (33%) followed by hypertension alone (30%), other causes (28%), and lastly diabetes alone (9%). For HD access, the majority of patients had arteriovenous grafts (AVGs) (44%) followed by arteriovenous fistulas (AVFs) (40%) and catheters (16%). The average time on HD at the time of echocardiogram was 3.7 ± 2.8 years.

Pulmonary hypertension
----------------------

42 patients (47%) met the def inition of PH of whom 18 patients (20%) had more severe PH. Patients with PH were older, and there was a trend for a female predominance in those with more severe PH; however, this did not reach statistical significance ([Table 1](#t1-ijgm-3-279){ref-type="table"}). Between the 3 groups, no significant differences were noted in the distribution of different ethnicities, type of access, years on HD, incidence of diabetes, hypertension, or history of coronary artery disease. Patients with PH did have a significantly lower body mass index (BMI) (*P \<* 0.02). Laboratory parameters such as haptoglobin, hemoglobin and LDH (potential indicators of hemolysis) were not significantly different between the 3 groups (data not shown).

Echocardiographic parameters are demonstrated in [Table 2](#t2-ijgm-3-279){ref-type="table"}. As expected, patients with PH had larger right atrial (RA) and right ventricular (RV) sizes, higher RAP and a trend towards decreased RV function. Left ventricular (LV) size did not change with increasing TR jet velocity; however, a trend towards more LV hypertrophy was noted. The mean LV ejection fraction (LVEF) in all patients was 58.4% ± 11% (range 22%--70%). With increasing TR jet velocity, a significant decrease in LV systolic function was noted. However, even in patients with TR ≥3 m/s, mean LVEF was preserved at 53.2% ± 14.7%. Patients with PH had significantly higher estimates of left sided filling pressures. Consistent with these findings, there was a trend towards larger left atrial size with increasing PAP ([Table 2](#t2-ijgm-3-279){ref-type="table"}). A pericardial effusion was more frequently present in patients with higher PAP (0% in group 1, 8% in group 2, and 33% in group 3). The occurrence of significant valvular disease was rare in all groups.

Echocardiographic data were available for the calculation of pulmonary capillary wedge pressure (PCWP) in 70 patients. Patients with PH had significantly higher PCWP ([Table 2](#t2-ijgm-3-279){ref-type="table"}). Correlation analysis revealed a significant correlation between PAP and PCWP (Pearson correlation coefficient = 0.5, *P* = 0.001).

Clinical outcome
----------------

At 12 months, a total of 14 deaths (15.6%) had occurred. Mortality was significantly higher in patients with PH (26%) compared with patients without PH (6%), and this was driven largely by increased mortality in patients with more significant PH (TR ≥ 3 m/s). By 12 months, mortality was 44% (8/18) in group 3 versus 6% (3/48) and 12.5% (3/24) in groups 1 and 2, respectively (*P* = 0.001). The Kaplan Meier survival curves are shown in [Figure 1](#f1-ijgm-3-279){ref-type="fig"}.

In exploratory analysis comparing survivors to non-survivors ([Table 3](#t3-ijgm-3-279){ref-type="table"}), there was no significant difference in age, race, gender, BMI, access type, and incidence of diabetes or hypertension, or history of coronary artery disease between the 2 groups. However, patients who died had been on HD for a significantly longer duration than survivors. In addition, patients who died had larger RA and RV sizes, worse RV function, more severe TR, and significantly higher RAP and PAP. There was no significant difference in LV size between the 2 groups, but non-survivors did show a trend towards lower LVEF than survivors. Moreover, PCWP was significantly higher in non-survivors ([Table 3](#t3-ijgm-3-279){ref-type="table"}).

Discussion
==========

Previously reported data has demonstrated that PH occurs in about 25%--45% of patients with ESRD on HD.[@b1-ijgm-3-279]--[@b3-ijgm-3-279] However, these analyses were retrospective, based on patients undergoing echocardiography for clinical indications (preselection bias) and were performed in non-US countries ([Table 4](#t4-ijgm-3-279){ref-type="table"}). This study is the first prospective evaluation of PH in dialysis patients in the US. Our study revealed that PH is highly prevalent in dialysis patients (47%), with 20% of the patients having echocardiographic evidence of more severe PH. This study further demonstrates that the presence of PH is associated with a significant increase in mortality with a 12-month mortality of 44% in patients with more severe PH. This is in relation to annual mortality rates of approximately 20% in dialysis patients in the US.[@b9-ijgm-3-279] Not surprisingly, this study provides evidence that the development of PH in dialysis patients may reflect the impact of chronic volume overload and chronically elevated left heart filling pressures.

Several mechanisms have been proposed for the development of PH in dialysis patients, and ultimately, a combination of multiple factors likely contributes to its development. PH may evolve due to the inability of the pulmonary circulation to accommodate increased cardiac output (resulting from increased volume, anemia, arteriovenous fistula) or as a result of increased pulmonary vascular stiffness due to endothelial dysfunction (decreased nitric oxide).[@b3-ijgm-3-279],[@b5-ijgm-3-279],[@b6-ijgm-3-279] In the current study, neither type of access nor anemia were associated with PH. The only echocardiographic parameters that were significantly associated with PH in the current study were PCWP and LV function. 63% of patients had echocardiographic evidence of elevated PCWP, and an elevated PCWP was associated with elevated RAP and PAP. Moreover, correlation analysis revealed a significant correlation between PAP and PCWP, suggesting that elevated PCWP may be a major contributor to PAP elevation.

Although there was a significant decrease in LV function with increasing PAP, the mean LVEF in patients with PH was still preserved (mean LVEF 53.2% ± 14.7%). Similarly, in subjects with higher estimates of PCWP, there was only a trend towards decreased LVEF. These findings suggest that diastolic heart failure with preserved LV systolic function may be the mechanism for elevated filling pressures in a significant proportion of patients. The elevated filling pressures in turn may contribute to the development of PH. In our study population, volume retention appeared to contribute more towards elevated filling pressures than severity of diastolic dysfunction. This is reflected by the observation that the increase in filling pressures was driven more by an increase in mitral E wave velocity rather than a decrease in tissue Doppler E velocity. However, the potential importance of multifactorial diastolic dysfunction, an increasingly frequent cause of PH in the non-dialysis patient population, should not be discounted as a contributor to PH and its outcome in the dialysis population.

Two previous studies also suggest a causal relationship between PCWP and PAP. Havlucu et al followed 25 dialysis and 23 pre-dialysis patients for 6 months. At the end of 6 months, left atrial diameter (LAD) (reflection of left-sided filling pressures), vena cava index (VCI) (reflection of RAP), and systolic PAP improved in the dialysis patients, whereas in pre-dialysis patients, VCI did not change and LAD and PAP actually increased. The authors concluded that effective HD and volume control (as reflected by decrease in LAD and VCI) may have resulted in improved PAP.[@b14-ijgm-3-279]

In another study, Barberato et al compared dialysis patients with normal and pseudonormal mitral inflow patterns, the latter reflecting elevated left-sided filling pressures. Interestingly, although mean LVEF was significantly lower in the pseudonormal group, it was still preserved on average (73% ± 7% versus 65% ± 10%, *P* \< 0.01). Moreover, systolic PAP was significantly higher in the pseudonormal group (38 ± 11 mmHg versus 20 ± 6 mmHg, *P* = 0.01).[@b15-ijgm-3-279] These results further support the findings in the current study that elevated filling pressures in dialysis patients are associated with preserved LV function and elevated PAP.

In ESRD patients, even in the presence of preserved LV systolic function, diastolic abnormalities with impaired LV relaxation and increased ventricular stiffness are not infrequent.[@b16-ijgm-3-279]--[@b18-ijgm-3-279] In our study population, 77% of the dialysis patients had echo evidence of abnormal diastolic function. Diastolic dysfunction in dialysis patients can be due to multiple factors. Left ventricular hypertrophy mainly as a result of hypertension is prevalent in dialysis patients and is strongly associated with impaired diastolic function. Furthermore, a large number of dialysis patients have diabetes, which by itself has been associated with increased myocardial stiffness and diastolic dysfunction. Other factors that may contribute to increased ventricular stiffness in ESRD patients include uremia and upregulation of various neurohormones.[@b19-ijgm-3-279]

In dialysis patients, the impact of PH on clinical outcomes has not previously been prospectively studied. While this is a cross-sectional study and may have suffered from survivor bias, given that the mortality was higher in the patients with PH, the survivor bias should predispose to an underestimation of the frequency of PH in the US dialysis patient population. In a recently published retrospective database review of HD patients receiving echocardiograms for clinical indications, 127 dialysis patients were evaluated, and the prevalence of PH was found to be 29%. Of the 37 patients with PH, 17 had PH at initiation of HD, and 20 patients developed PH after HD initiation. Survival was significantly higher in patients without PH. The 1-, 3-, and 5-year mortality in patients with and without PH were 21.4% versus 3.5%, 57.1% versus 21.2%, and 74.8% versus 33.6% respectively.[@b1-ijgm-3-279] Similar findings were noted in the current study: at 12 months follow-up, mortality was 26% in patients with PH and 6% in patients without PH. Interestingly, with respect to all-cause hospitalizations (including emergency room visits), no significant difference was found amongst the 3 groups. Thus, morbidity by this definition amongst dialysis patients appears to be very high irrespective of PAP.

In the current study, when comparing survivors with non-survivors, PAP and PCWP were significantly higher in non-survivors. On the one hand, this may reflect the progression of diastolic heart failure with elevated PCWP eventually resulting in PH, which then carries a poor long-term prognosis. Alternatively, PH may have developed as a result of other causes, may not necessarily be associated with elevated PCWP, and may thus independently be a poor prognostic marker.

No relation was found between the nature of the dialysis access and the presence of PH. This is not unexpected. There is a clear rationale for aggravation of heart failure in patients with established PH or diastolic dysfunction due to the higher output imposed by a chronic graft of fistula. However, there is a very low likelihood that a 25%--30% increase in basal cardiac output over a relatively short period of time (years as opposed to decades) would be likely to predispose to the high flow induced changes in the pulmonary vascular bed leading to PH. The development of PH is remarkably infrequent (about 4%) in patients with common congenital heart disease such as ASD.

Limitations
===========

We included patients in whom PAP could not be measured due to insufficient TR in the normal group (group 1). We did ensure that these patients did not have any other echocardiographic signs indicating the presence of PH. Secondly, we used a TR jet cutoff of ≥2.5 m/s for the classification of PH. Assuming a RAP of 10 mmHg, this would equate to a PAP of ≥35 mmHg. In the setting of lower RAP, these patients may have been misclassified as having higher PAP. Although these 2 scenarios may have led to misclassification by potentially including PH patients in the normal group and normal patients in the PH group, we were still able to identify a difference in prognosis between the groups. Due to the small number of overall events, a multivariable regression analysis could not be performed to evaluate the extent to which PH independently contributed to mortality. Thus, although PH is associated with higher mortality, our study was not able to ascertain causality versus association between PH and mortality or whether PH is merely an indicator of sicker patients. We believe, however, that this approach in this cross-sectional analysis conservatively provides a lower estimate of the prevalence and impact of PH in chronic ESRD patient on dialysis.

Conclusion
==========

In this first prospective study of PH in US dialysis patients, at a single center, we found that PH is highly prevalent and is associated with echocardiographic evidence of elevated left-sided filling pressures and higher mortality. The clinical importance of PH appears to be as a marker of disease severity, as a potential target of therapy, and as an important prognostic indicator. While multiple factors may contribute to the development of PH in dialysis patients our results suggest that chronic volume overload, and/or diastolic dysfunction may contribute to the development of PH, which is associated with poorer survival. This suggests that the presence of PH should be incorporated in the decision making for renal transplantation, since PH is associated with worse survival, and appears to improve after renal transplantation.[@b2-ijgm-3-279]

The results of the current study demonstrating the frequency and impact of PH in the US dialysis population underline the importance of adequate volume removal, and potentially the importance of future therapies targeting PH and diastolic dysfunction.

This project was supported by a grant from the Frueauff Foundation. The authors wish to thank: Biosound for providing the ultrasound machine; Fresenius and the physicians, nurses, and patients, and Dr Wadi N Suki, Medical Director at the Medical Center Kidney Clinic, Houston, Texas for their cooperation in this study.

**Support and financial disclosure declaration**

Funding for this study was obtained from the Frueauff Foundation, a nonprofit, non-industry organization, which supports limited medical and scientific studies. In addition, as stated in the acknowledgments, Biosound provided an echo machine free of charge to undertake the external echocardiograms which were done at the dialysis units.

**Conflict of interest**

Dr Frost has received funding for FDA approved multicenter studies in pulmonary hypertension from Bayer, Actelion, Gilead, Lilly, United Therapeutics, Novartis and Pfizer. She is on the speaker bureau and/or has received honoraria for participation in advisory boards on PH from Gilead, Pfizer, United Therapeutics and Actelion. The other authors declare no conflicts of interest.

![Kaplan Meier survival estimates based on presence, absence, and degree of PH by TR jet: group 1 = no TR, and TR \< 2.5 m/s; group 2 = TR 2.5--3.0 m/s; group 3 = TR \> 3.0 m/s (*P* = 0.0004). At 12 months, mortality was 44% (8/18) in group 3 versus 6% (3/48) and 12.5% (3/24) in groups 1 and 2, respectively (*P* = 0.001). The *P* = 0.0004 is based on the time to event analysis and signifies an overall difference between the 3 curves/groups. *P* = 0.001 is based on a chi-square test for the number of deaths by 12 months between the 3 groups.\
**Abbreviation:** TR, tricuspid regurgitant.](ijgm-3-279f1){#f1-ijgm-3-279}

###### 

Baseline clinical characteristics

                      All n = 90    \<2.5 m/s n = 48   2.5--3.0 m/s n = 24   \>3.0 m/s n = 18   *P*-value
  ------------------- ------------- ------------------ --------------------- ------------------ -----------
  Age (years)         58.3 ± 15.4   54.5 ± 14.3        62.5 ± 13.6           62.4 ± 18.3        0.05
  Gender (% male)     59M (66%)     30M (63%)          20M (83%)             9M (50%)           0.06
  Ethnicity                                                                                     
  AA                  58 (64%)      35 (73%)           13 (54%)              10 (56%)           
  C                   16 (18%)      7 (15%)            3 (13%)               6 (33%)            0.07
  H                   16 (18%)      6 (13%)            8 (33%)               2 (11%)            
  BMI                 27.2 ± 6.0    29.6 ± 5.9         25.1 ± 4.3            24.0 ± 5.7         \<0.02
  Dialysis access                                                                               
  AVF                 35 (40%)      20 (43%)           12 (52%)              3 (17%)            
  AVG                 39 (44%)      20 (43%)           8 (35%)               11 (61%)           0.23
  Ca                  14 (16%)      7 (15%)            3 (13%)               4 (22%)            
  Years on dialysis   3.6 ± 2.9     3.8 ± 2.7          3.1 ± 2.8             3.6 ± 3.3          0.67

**Abbreviations:** F, female; M, male; AA, African American; C, Caucasian; H, Hispanic; BMI, body mass index; AVF, arteriovenous fistula; AVG, arteriovenous graft; Ca, catheter.

###### 

Echocardiographic parameters

  TR velocity                                          \<2.5 m/s n = 48   2.5--3.0 m/s n = 24   \>3.0 m/s n = 18   *P*-value
  ---------------------------------------------------- ------------------ --------------------- ------------------ -----------
  Right heart echo parameters                                                                                      
  RA volume (mL)                                       41.6 ± 20.3        51 ± 20.3             70.1 ± 27.9        \<0.02
  RV apical diameter (cm)                              3.5 ± 0.7          3.6 ± 0.5             4.2 ± 0.7          0.003
  RV Tei                                               0.14 ± 0.2         0.19 ± 0.19           0.28 ± 0.17        0.053
  Annular descent (cm)                                 1.9 ± 0.6          1.8 ± 0.4             1.6 ± 0.7          0.29
  RV fractional shortening                             40.8 ± 6.3         41 ± 8.7              35.4 ± 9.5         0.1
  RAP (mmHg)                                           7.4 ± 3.4          9.6 ± 4.1             12.8 ± 4.6         \<0.02
  Left heart echo parameters                                                                                       
  LVID (cm)                                            4.5 ± 0.7          4.7 ± 0.6             4.6 ± 0.7          0.534
  LVEF (%)                                             61.1 ± 7.4         56.9 ± 11.2           53.2 ± 14.7        0.017
  LA volume (mL)                                       60.7 ± 22.1        62.5 ± 19.4           74.8 ± 26.5        0.085
  PCWP (mmHg)                                          15.6 ± 5.3         19.5 ± 7.7            24.9 ± 7.9         \<0.02
  LVH[a](#tfn2-ijgm-3-279){ref-type="table-fn"} (cm)   1.4 ± 0.6          1.5 ± 0.6             1.9 ± 0.6          0.1

**Note:** average wall thickness of interventricular septum and posterior wall measured in the parasternal long axis view.

**Abbreviations:** TR, tricuspid regurgitant; RA, right atrial; RV, right ventricular; RAP, right atrial pressure; LVID, left ventricular internal dimension; LVEF, left ventricular ejection fraction; LA, left atrial; PCWP, pulmonary capillary wedge pressure.

###### 

Analysis by survivors and non-survivors

                             Survivors n = 76     Non-survivors n = 14   *P*-value
  -------------------------- -------------------- ---------------------- -----------
  Age                        57.4 ± 15            62.79 ± 16.8           0.23
  Race                       49AA, 14C, 13H       9AA, 2C, 3H            0.89
  Gender                     52M, 24F             7M, 7F                 0.18
  BMI                        27.549 ± 6           25.55 ± 5.8            0.27
  Access                     33AVF, 32AVG, 10Ca   6AVF, 3AVG, 4Ca        0.2
  Years on HD                3.4 ± 2.6            5.4 ± 3.4              0.02
  RA volume                  47.4 ± 23.4          63.4 ± 25.2            0.03
  RA fractional shortening   38.8 ± 9.4           28.7 ± 15.7            0.008
  RV apical diameter         3.6 ± 0.7            4.0 ± 0.6              0.07
  RV function                1.1 ± 0.4            1.7 ± 0.9              0.001
  Annular descent            1.8 ± 0.6            1.5 ± 0.7              0.06
  RV fractional shortening   40.5 ± 7.2           35 ± 10.9              0.07
  TR severity                1.4 ± 0.7            1.9 ± 1.0              0.01
  RAP                        8.7 ± 3.9            12.3 ± 5.6             0.006
  PAP                        39.4 ± 10.5          56.9 ± 19.7            \<0.02
  LVID                       4.6 ± 0.6            4.6 ± 0.8              0.87
  LVEF                       59.1 ± 9.7           54.7 ± 14.5            0.16
  PCWP                       17.3 ± 6.6           23.9 ± 8.8             0.01

**Abbreviations:** F, female; M, male; AA, African American; C, Caucasian; H, Hispanic; AVF, arteriovenous fistula; AVG, arteriovenous graft; Ca, Catheter; BMI, body mass index; HD, hemodialysis; RA, right atrial; RV, right ventricular; TR, tricuspid regurgitant; RAP, right atrial pressure; PAP, pulmonary artery pressure; LVID, left ventricular internal dimension; LVEF, left ventricular ejection fraction; PCWP, pulmonary capillary wedge pressure.

###### 

Review of studies evaluating pulmonary hypertension in patients with end stage renal disease

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                    Country of study   Number of patients                              Mean age                     Male/female           Incidence of PH   Reason for HD                   Factors associated with PH                                                                       Long-term outcome                                                                                                     Notes
  --------------------------------- ------------------ ----------------------------------------------- ---------------------------- --------------------- ----------------- ------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abdelwhab et al[@b3-ijgm-3-279]   Egypt              45                                              50.8 ± 8                     58%/42%               44.4%                                                                                                                                                                                                                                                                    

  Mazdeh et al[@b21-ijgm-3-279]     Iran               62                                              51.1 ± 17.3                  18/14                 52%               Dm and HTN                                                                                                                                                                                                                                             

  Tarrass et al[@b22-ijgm-3-279]    Morocco            86                                              45.4 ± 14.4                  40/46                 26.7%             GN\>\>HTN                                                                                                                                                                                                                                              Excluded COPD, collagen vascular disease, SLE, LVEF \< 50%, significant valvular disease

  Yigla et al[@b2-ijgm-3-279]       Israel             58                                                                                                 40%               Dm\>HTN\>GN                     High CO, lower hemoglogin, shorter duration of HF                                                At 24--60 months follow-up, mortality was 30 versus 8.5% in patients with and without PH                              After HD in 9 patients, PAP decreased in 3 patients, increased in 4 patients and remained same in 2 patientsIn 4/5 HD patients, PAP normalized after renal transplantationIn 4 patients, CO and PAP decreased with access compression

  Yigla et al[@b23-ijgm-3-279]      Israel             127[a](#tfn5-ijgm-3-279){ref-type="table-fn"}   No PH: 61.2 ± 13.4\          No PH: 56/34\         29%               Dm\>Pyelonephritis\>\                                                                                                            1-, 3-, and 5-year mortality in patients with and without PH were 21.4% vs 3.5%, 57.1% vs 21.2%, and 74.8% vs 33.6%   Predictors of mortality: Univariate analysis -- age at onset of HD, valvular diseases, PH prevalence before HD, PH incidence after HDMultivariate analysis -- development of PH before and after HD initiation
                                                                                                       PH before HD: 63.3 ± 14.0\   PH before HD: 10/7\                     HTN\>\                                                                                                                                                                                                                                                 
                                                                                                       PH after HD: 62.9 ± 17.4     PH after HD: 12/8                       Nephrolithiasis\>\                                                                                                                                                                                                                                     
                                                                                                                                                                            Polycystic kidney disease\>GN                                                                                                                                                                                                                          

  Amin et al[@b20-ijgm-3-279]       Egypt              51                                              PH: 44 ± 10\                 PH: 4/11\             29%               HTN\>\                                                                                                                                                                                                                                                 No significant difference in Tc 99m diphosphate scintigraphy, PTH, Ca, phosphorus between PH and no PH patients -- Higher incidence of PH in women
                                                                                                       No PH: 41 ± 11               No PH: 24/12                            Pyelonephritis = GN\                                                                                                                                                                                                                                   
                                                                                                                                                                            \>Dm                                                                                                                                                                                                                                                   

  Havlucu et al[@b14-ijgm-3-279]    Turkey             25                                              60.1 ± 15.6                  40%/60%               56%               HTN/GN/Dm                       Higher CO, longer duration of CRI, higher PTH+Ca/PO4 product, higher probability of having AVF                                                                                                                         Excluded cardiac etiology (diastolic/systolic dysfunction)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** This included patients from Yigla[@b2-ijgm-3-279].

**Abbreviations:** PH, pulmonary hypertension; HD, hemodialysis; Dm, diabetes mellitus; HTN, hypertension; GN, glomerulonephritis; CO, cardiac output; HF, heart failure; COPD, chronic obstructive pulmonary disease; SLE, systemic lupus erythematosus; LVEF, left ventricular ejection fraction; PAP, pulmonary artery pressure; CRI, chronic renal insufficiency; PTH, parathyroid hormone; AVF, arteriovenous fistula.
